avapro has been researched along with Kidney Diseases in 32 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on results of large-scale controlled trials of irbesartan (I), valsartan (V) and amlodipine (A) (PRIME and MARVAL) we carried out the Markov s modeling of their pharmacoeconomic parameters in arterial hypertension (AH) combined with diabetes mellitus type 2 (DM 2) and microalbuminuria (MAU) projected for 8-years perspective." | 5.13 | [Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus]. ( Belousov, DIu; Belousov, IuB; Shestakova, MV, 2008) |
| "In children with chronic kidney disease the effects of the angiotensin II antagonist irbesartan on arterial pressure and proteinuria mimic those observed with the converting enzyme inhibitors." | 5.09 | Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. ( Bianchetti, MG; Teuffel, O; von Vigier, RO; Zberg, PM, 2000) |
| " In group A, 8 weeks of treatment induced a two- to nine-fold reduction in urinary cytokine levels (GCSF, GM-CSF, IFN-γ, IL-1a, IL-11, IL-12p40, MCP-2, MIP-1a), while increasing the dosage to 300 mg/d further decreased the excretion of GCSF, GM-CSF, IL-12p40, MCP-2 and MIP-1a by week 18." | 2.77 | Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease. ( Huang, HQ; Liu, BC; Lü, LL; Ni, J; Zheng, M, 2012) |
| " Based on these pharmacokinetic and safety data, no dosage adjustments of IRBE are necessary for patients with RI, HI, or HF, or based on patient age, gender, or race." | 2.41 | Pharmacokinetics of irbesartan are not altered in special populations. ( Marino, MR; Vachharajani, NN, 2002) |
| " Irbesartan displays linear, dose related pharmacokinetics and, with the exception of tasosartan's active metabolite, has the longest elimination half-life of the AIIRA (11 to 15 h)." | 2.40 | The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. ( Brunner, HR, 1997) |
| " Nifedipine and irbesartan were taken after discharge, and the dosage was reduced gradually under supervision." | 1.48 | Hypertensive crisis with 2 target organ impairment induced by glycyrrhizin: A case report. ( Fan, X; Li, J; Wang, Q, 2018) |
| "Aliskiren is an orally active direct renin inhibitor approved for the treatment of hypertension." | 1.34 | Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. ( Bigler, H; Bizot, MN; Dieterich, HA; Dole, WP; Howard, D; Vaidyanathan, S; Yeh, C, 2007) |
| " However, nephrotoxicity is the major adverse effect of CsA use." | 1.32 | Amelioration of cyclosporine nephrotoxicity by irbesartan, A selective AT1 receptor antagonist. ( Chander, H; Chander, V; Chopra, K; Singh, D; Tirkey, N, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 24 (75.00) | 29.6817 |
| 2010's | 5 (15.63) | 24.3611 |
| 2020's | 2 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Z | 2 |
| Zhai, J | 2 |
| Zhang, T | 2 |
| He, L | 2 |
| Ma, S | 2 |
| Zuo, Q | 2 |
| Zhang, G | 2 |
| Wang, Y | 1 |
| Guo, Y | 2 |
| Wang, X | 1 |
| Li, J | 2 |
| Fan, X | 1 |
| Wang, Q | 1 |
| Takenaka, T | 1 |
| Inoue, T | 1 |
| Ohno, Y | 1 |
| Miyazaki, T | 1 |
| Nishiyama, A | 1 |
| Ishii, N | 1 |
| Suzuki, H | 1 |
| Seccia, TM | 1 |
| Caroccia, B | 1 |
| Gioco, F | 1 |
| Piazza, M | 1 |
| Buccella, V | 1 |
| Guidolin, D | 1 |
| Guerzoni, E | 1 |
| Montini, B | 1 |
| Petrelli, L | 1 |
| Pagnin, E | 1 |
| Ravarotto, V | 1 |
| Belloni, AS | 1 |
| Calò, LA | 1 |
| Rossi, GP | 1 |
| Belousov, IuB | 1 |
| Shestakova, MV | 1 |
| Belousov, DIu | 1 |
| Ghali, JK | 1 |
| Schillaci, G | 1 |
| Pucci, G | 1 |
| Pirro, M | 1 |
| Ariyoshi, Y | 1 |
| Mizumoto, K | 1 |
| Gersak, K | 1 |
| Cvijic, M | 1 |
| Cerar, LK | 1 |
| Russell, JC | 1 |
| Kelly, SE | 1 |
| Vine, DF | 1 |
| Proctor, SD | 1 |
| Zhao, G | 1 |
| Zhao, H | 1 |
| Tu, L | 1 |
| Xu, X | 1 |
| Zheng, C | 1 |
| Jiang, M | 1 |
| Wang, P | 1 |
| Wang, D | 1 |
| Ni, J | 1 |
| Huang, HQ | 1 |
| Lü, LL | 1 |
| Zheng, M | 1 |
| Liu, BC | 1 |
| Eguchi, K | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Terra, SG | 1 |
| Li, S | 1 |
| Cao, B | 1 |
| Feng, QH | 1 |
| Li, XZ | 1 |
| Chander, V | 1 |
| Singh, D | 1 |
| Tirkey, N | 1 |
| Chander, H | 1 |
| Chopra, K | 1 |
| Dimopoulos-Xicki, L | 1 |
| Haas, M | 1 |
| Vogt, L | 1 |
| Navis, G | 1 |
| de Zeeuw, D | 1 |
| de Gracia, MC | 1 |
| Molina, M | 1 |
| Navarro, MJ | 1 |
| Garcia Hernández, MA | 1 |
| Xie, HH | 1 |
| Shen, FM | 1 |
| Zhang, XF | 1 |
| Jiang, YY | 1 |
| Su, DF | 1 |
| Tschöpe, C | 1 |
| Tschöpe, R | 1 |
| Unger, T | 1 |
| Meier, CM | 1 |
| Simonetti, GD | 1 |
| Ghiglia, S | 1 |
| Fossali, E | 1 |
| Salice, P | 1 |
| Limoni, C | 1 |
| Bianchetti, MG | 2 |
| Vaidyanathan, S | 1 |
| Bigler, H | 1 |
| Yeh, C | 1 |
| Bizot, MN | 1 |
| Dieterich, HA | 1 |
| Howard, D | 1 |
| Dole, WP | 1 |
| Tu, X | 1 |
| Chen, X | 1 |
| Xie, Y | 1 |
| Shi, S | 1 |
| Wang, J | 1 |
| Chen, Y | 1 |
| Coronel, F | 1 |
| Cigarrán, S | 1 |
| García-Mena, M | 1 |
| Herrero, JA | 1 |
| Calvo, N | 1 |
| Pérez-Flores, I | 1 |
| Brunner, HR | 1 |
| von Vigier, RO | 1 |
| Zberg, PM | 1 |
| Teuffel, O | 1 |
| Ramahi, TM | 1 |
| Studney, D | 1 |
| Marino, MR | 1 |
| Vachharajani, NN | 1 |
6 reviews available for avapro and Kidney Diseases
| Article | Year |
|---|---|
[Pharmacological properties and clinical efficacy of the long-active angiotensin receptor blocker (ARB) irbesartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Compounds; Delay | 2009 |
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2002 |
The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Interactions; Hu | 1997 |
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitor | 2001 |
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2002 |
Pharmacokinetics of irbesartan are not altered in special populations.
Topics: Adolescent; Adult; Aged; Biphenyl Compounds; Child; Female; Heart Failure; Humans; Hypertension; Irb | 2002 |
7 trials available for avapro and Kidney Diseases
| Article | Year |
|---|---|
[Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Co | 2008 |
Influence of irbesartan on the urinary excretion of cytokines in patients with chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Creatinine; Cross-Over | 2012 |
Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?
Topics: Adolescent; Adult; Aged; Biological Availability; Biphenyl Compounds; Confidence Intervals; Dose-Res | 2005 |
[Effect of irbesartan in proteinuric non-diabetic renal disease].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Female; Humans; Irbesartan; Kidn | 2005 |
Palatability of angiotensin II antagonists among nephropathic children.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Bipheny | 2007 |
[Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Disease | 2008 |
Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
Topics: Adolescent; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2000 |
19 other studies available for avapro and Kidney Diseases
| Article | Year |
|---|---|
Canagliflozin ameliorates epithelial-mesenchymal transition in high-salt diet-induced hypertensive renal injury through restoration of sirtuin 3 expression and the reduction of oxidative stress.
Topics: Animals; Canagliflozin; Catalase; Diet; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Hyperte | 2023 |
Canagliflozin and irbesartan ameliorate renal fibrosis via the TGF-β1/Smad signaling pathway in Dahl salt-sensitive rats.
Topics: Animals; Blood Pressure; Canagliflozin; Fibrosis; Hypertension; Irbesartan; Kidney; Kidney Diseases; | 2023 |
Hypertensive crisis with 2 target organ impairment induced by glycyrrhizin: A case report.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Cholangitis; | 2018 |
Calcitriol supplementation improves endothelium-dependent vasodilation in rat hypertensive renal injury.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcitriol; Di | 2014 |
Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis.
Topics: Actins; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Biphenyl Compounds | 2016 |
Irbesartan for heart failure with preserved ejection fraction.
Topics: Anemia; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Creatinine; Heart Failure; Hosp | 2009 |
Irbesartan for heart failure with preserved ejection fraction.
Topics: Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Heart Failure; Humans; | 2009 |
Angiotensin II receptor blockers in pregnancy: a report of five cases.
Topics: Abnormalities, Drug-Induced; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphe | 2009 |
Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR : LA-cp rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiovascular Diseases; Infla | 2009 |
Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Fibrosis; Irbesartan; Kidney D | 2010 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Bip | 2003 |
[Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibiotics, Antineoplastic; Biphenyl Com | 2003 |
Amelioration of cyclosporine nephrotoxicity by irbesartan, A selective AT1 receptor antagonist.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cyclosporine; Immunosuppressiv | 2004 |
[Therapeutic implications of ACE-gene polymorphism].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Aorta; Atenolol; Baroreflex; Biphenyl Compounds; Blood Pressure; C | 2006 |
[Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
Topics: Adult; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compo | 2006 |
[Treatment of hypertension can do more. Using chances for organ protection].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular | 2006 |
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment.
Topics: Administration, Oral; Amides; Biphenyl Compounds; Drug Therapy, Combination; Fumarates; Humans; Irbe | 2007 |
Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biphenyl Compounds; Blood | 2008 |